HOWL
Closed
Werewolf Therapeutics Inc
1.05
-0.04 (-3.67%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.09
Day's Range: 1.025 - 1.119
Send
sign up or login to leave a comment!
When Written:
2.47
Werewolf Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for cancer treatment. The company was founded in 2017 and is based in Cambridge, Massachusetts.
The company's technology platform is based on the use of engineered cytokines, which are proteins that can stimulate the immune system to attack cancer cells. Werewolf Therapeutics' lead product candidate, WTX-124, is a cytokine-based therapy that is designed to activate immune cells in the tumor microenvironment and enhance their ability to kill cancer cells.
WTX-124 is currently in Phase 1 clinical trials for the treatment of solid tumors. The company is also developing other cytokine-based therapies for the treatment of cancer.
Werewolf Therapeutics has partnerships and collaborations with several leading academic institutions, including Harvard Medical School and the Dana-Farber Cancer Institute. The company has also received funding from venture capital firms and other investors, including MPM Capital, Longwood Fund, and AbbVie Ventures.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company's technology platform is based on the use of engineered cytokines, which are proteins that can stimulate the immune system to attack cancer cells. Werewolf Therapeutics' lead product candidate, WTX-124, is a cytokine-based therapy that is designed to activate immune cells in the tumor microenvironment and enhance their ability to kill cancer cells.
WTX-124 is currently in Phase 1 clinical trials for the treatment of solid tumors. The company is also developing other cytokine-based therapies for the treatment of cancer.
Werewolf Therapeutics has partnerships and collaborations with several leading academic institutions, including Harvard Medical School and the Dana-Farber Cancer Institute. The company has also received funding from venture capital firms and other investors, including MPM Capital, Longwood Fund, and AbbVie Ventures.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








